Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gneiss, C; Koudouovoh-Tripp, PM; Ropele, S; Gotwald, T; Ehling, R; Lutterotti, A; Aichner, F; Ladurner, G; Eggers, C; Schautzer, F; Künz, B; Millonig, A; Aspeck, E; Reindl, M; Berger, T; Fazekas, F; Deisenhammer, F.
Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Mult Scler. 2009; 15(12): 1481-1488.
Doi: 10.1177/1352458509347153
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Aspeck Engelbert
- Fazekas Franz
- Ropele Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Neutralizing antibodies against interferon-beta are associated with a reduction of the efficacy of this drug. Continuing treatment leads to a decline or even loss of neutralizing antibodies over years. No strategies are currently available to shorten the period of neutralizing antibody positivity. The objective of this study was to investigate the effect of switching between high and low immunogenic interferon-beta products on neutralising antibody titres. Twenty-four patients treated with the subcutaneously administered interferon-beta 1b or 1a and high titres of neutralizing antibodies were included. At baseline interferon-beta therapy was interrupted for 3 months and two pulses of high dose methylprednisolone were applied. Patients were then randomized to receive either the previous interferon-beta preparation or the low immunogenic intramuscular interferon-beta 1a. The primary end-point was the change of neutralizing antibody titres 12 months after randomization. Twelve patients were switched to interferon-beta 1a intramuscularly and 12 patients remained on previous treatment. Median neutralizing antibody titres were 846 NU at baseline and 196 NU at the end of the study. The median change of neutralizing antibody titres did not differ significantly between therapy switchers and non-switchers. Baseline and final neutralizing antibody titres correlated significantly. In conclusion, neither switching nor continuous therapy with any subcutaneous interferon-beta preparation significantly changed neutralizing antibody titres.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antibodies, Neutralizing - blood
- Antibodies, Neutralizing -
- Drug Administration Schedule -
- Glucocorticoids - administration and dosage
- Humans -
- Immunologic Factors - administration and dosage
- Infusions, Intravenous -
- Injections, Intramuscular -
- Injections, Subcutaneous -
- Interferon-beta - administration and dosage
- Magnetic Resonance Imaging -
- Methylprednisolone - administration and dosage
- Middle Aged -
- Multiple Sclerosis, Relapsing-Remitting - drug therapy
- Pulse Therapy, Drug -
- Recurrence -
- Time Factors -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- biological markers
- clinical trial
- interferon-beta
- multiple sclerosis
- neutralizing antibodies